These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24787905)

  • 1. Central body fat changes in men affected by post-surgical hypogonadotropic hypogonadism undergoing testosterone replacement therapy are modulated by androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Buldreghini E; Lenzi A; Balercia G
    Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):908-13. PubMed ID: 24787905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor gene CAG repeat polymorphism independently influences recovery of male sexual function after testosterone replacement therapy in postsurgical hypogonadotropic hypogonadism.
    Tirabassi G; Delli Muti N; Corona G; Maggi M; Balercia G
    J Sex Med; 2014 May; 11(5):1302-8. PubMed ID: 24593124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of testosterone replacement therapy on bone metabolism in male post-surgical hypogonadotropic hypogonadism: focus on the role of androgen receptor CAG polymorphism.
    Tirabassi G; delli Muti N; Gioia A; Biagioli A; Lenzi A; Balercia G
    J Endocrinol Invest; 2014 Apr; 37(4):393-400. PubMed ID: 24458833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism.
    Tirabassi G; Corona G; Biagioli A; Buldreghini E; delli Muti N; Maggi M; Balercia G
    J Sex Med; 2015 Feb; 12(2):381-8. PubMed ID: 25443437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Receptor Gene CAG Repeat Polymorphism Regulates the Metabolic Effects of Testosterone Replacement Therapy in Male Postsurgical Hypogonadotropic Hypogonadism.
    Tirabassi G; Delli Muti N; Corona G; Maggi M; Balercia G
    Int J Endocrinol; 2013; 2013():816740. PubMed ID: 24454369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study.
    Stanworth RD; Akhtar S; Channer KS; Jones TH
    Eur J Endocrinol; 2014 Feb; 170(2):193-200. PubMed ID: 24165020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men?
    Lapauw B; Goemaere S; Crabbe P; Kaufman JM; Ruige JB
    Eur J Endocrinol; 2007 Mar; 156(3):395-401. PubMed ID: 17322500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible role of
    Firouzi V; Borjian Boroujeni P; Rokhsat Talab Z; Mohammadi M; Sadighi Gilani MA; Sabbaghian M; Mohseni Meybodi A
    Syst Biol Reprod Med; 2019 Aug; 65(4):326-332. PubMed ID: 31030566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of testosterone replacement therapy.
    Zitzmann M
    Pharmacogenomics; 2009 Aug; 10(8):1341-9. PubMed ID: 19663677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes.
    Stanworth RD; Kapoor D; Channer KS; Jones TH
    Eur J Endocrinol; 2008 Dec; 159(6):739-46. PubMed ID: 18805913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study.
    Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
    J Clin Endocrinol Metab; 2003 May; 88(5):2049-54. PubMed ID: 12727953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of gonadotropin administration for spermatogenesis induction in hypogonadotropic hypogonadism: a possible role of androgen receptor CAG repeat polymorphism and therapeutic measures.
    Giagulli VA; Triggiani V; Corona G; Carbone MD; Tafaro E; Licchelli B; Resta F; Sabbà C; Maggi M; Guastamacchia E
    Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):236-42. PubMed ID: 22385118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism.
    Crabbe P; Bogaert V; De Bacquer D; Goemaere S; Zmierczak H; Kaufman JM
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3604-10. PubMed ID: 17579205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism?
    Francomano D; Greco EA; Lenzi A; Aversa A
    J Sex Med; 2013 Oct; 10(10):2373-81. PubMed ID: 23844628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study.
    Nielsen TL; Hagen C; Wraae K; Bathum L; Larsen R; Brixen K; Andersen M
    Eur J Endocrinol; 2010 Apr; 162(4):795-804. PubMed ID: 20133446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthropometry in Klinefelter syndrome--multifactorial influences due to CAG length, testosterone treatment and possibly intrauterine hypogonadism.
    Chang S; Skakkebæk A; Trolle C; Bojesen A; Hertz JM; Cohen A; Hougaard DM; Wallentin M; Pedersen AD; Østergaard JR; Gravholt CH
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E508-17. PubMed ID: 25514102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of testosterone replacement and its pharmacogenetics on physical performance and metabolism.
    Zitzmann M
    Asian J Androl; 2008 May; 10(3):364-72. PubMed ID: 18385898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone benefits of testosterone replacement therapy in male hypogonadism.
    Tirabassi G; Biagioli A; Balercia G
    Panminerva Med; 2014 Jun; 56(2):151-63. PubMed ID: 24994579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
    Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
    Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.